The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.
Header
News Archive
Showing 45 results
November 2025
-
Media Release
Novartis Canada Unveils 2025 Health Equity Initiative Winners, Awarding Over $560,000 at Montreal Ceremony with Federal Health Minister, the Honourable Marjorie Michel, in Attendance
The Novartis Health Equity Initiative continues to support projects tackling systemic health disparities and promoting equitable access to healthcare across Canada.To date, the initiative drew over… -
Media Release
Novartis Canada Welcomes Dimitri Gitas as New Country President
MONTREAL, QC, November 25, 2025 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is pleased to announce the appointment of Dimitri Gitas as Country…
July 2025
-
Media Release
Health Canada expands approval of Scemblix®, making it an option for newly diagnosed and previously treated chronic myeloid leukemia (CML) patients
• Scemblix® is first to show superior efficacy and a favourable safety and tolerability profile in a Phase III trial vs. all standard of care (SoC) therapies.1,2• … -
Media Release
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS)
• Important milestone towards public reimbursement for a new treatment option for eligible Canadian patients living with moderate to severe hidradenitis suppurativa (HS)• … -
Media Release
Quebec implements public reimbursement of Pluvicto® – a defining milestone for radioligand therapy in Canada
Pluvicto® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic castration-resistant prostate cancerMomentum builds…
June 2025
-
Media Release
Health Canada approves Novartis' KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence
Despite endocrine therapy (ET), the risk of recurrence for people diagnosed with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) early breast cancer (eBC… -
Media Release
The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) returns for its 22nd year at ASCO 2025
For over two decades, NOYCIA has fueled emerging research in Canada, driving scientific knowledge in cancerMontreal, QC – June 10, 2025 – Novartis Canada is pleased to announce the winners…